Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11967288 | 0.86 | ADRA1A (0.32) | ADRA1ACYP17A1CYP1A2 | |
| SCHEMBL18655420 | 0.74 | — | — | |
| SCHEMBL14553278 | 0.72 | CYP17A1 (0.36) | ADRA1ACYP17A1CYP1A2 | |
| SCHEMBL24768960 | 0.69 | TLR9 (0.31) | — | |
| SCHEMBL31708457 | 0.68 | ADRA1A (0.33) | ADRA1ACYP17A1CYP1A2 | |
| SCHEMBL23991218 | 0.64 | ADRA1A (0.32) | ADRA1ACYP17A1CYP1A2 | |
| SCHEMBL23990554 | 0.63 | ATM (0.35) | ADRA1A | |
| SCHEMBL24768869 | 0.62 | — | — | |
| SCHEMBL23990535 | 0.62 | NPC1 (0.33) | ADRA1A | |
| SCHEMBL25869364 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | ADRA1A 306/4885CYP17A1 103/4885CYP1A2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.